20 Jun 2016 16:24
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Shareholder notification
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device clients, has been informed today that Mr David Newton no longer holds a notifiable shareholding in the Company.
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | |
Jonathan Hartshorn, Chief Financial Officer | Tel: +353 153 93 269 | |
Aoife O Farrell, Marketing Manager | Tel: +353 153 93 269 | |
|
| |
Davy (Nominated Adviser, ESM Adviser and Joint Broker) | Tel: +353 1 679 6363 | |
Fergal Meegan / Matthew DeVere White (Corporate Finance) |
| |
Paul Burke (Corporate Broking) |
| |
|
| |
Hybridan LLP (Joint-Broker) |
| |
Claire Louise Noyce | Tel: 020 3764 2341 | |
|
| |
Walbrook PR Ltd | Tel: 020 7933 8787 or venn@walbrookpr.com | |
Paul McManus | Mob: 07980 541 893 | |
Lianne Cawthorne | Mob: 07584 391 303 | |
About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
For more information about the Company, please visit: www.vennlifesciences.com
ORPH.L (ORPH)